Rafarma Pharmaceuticals, Inc. (OTCPK: RAFA)
Health Care · Pharmaceuticals · US
$0.04
+3.65% today · -41.9% 1Y
Rafarma Pharmaceuticals, Inc. (OTCPK: RAFA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $3.13M and employs 700 people.
Over the last twelve months the share price has lost 41.9%, trading between 0.00 and 0.10.
Tweenvest scores Rafarma Pharmaceuticals, Inc. across four factors: value 85/100. Its strongest factor is value.
RAFA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $3.13M
- Revenue (TTM)
- $133.33K
- P/E
- —
- EPS
- -0.01
- Dividend yield
- —
- Beta (5Y)
- 0.59
- 52-week high
- $0.10
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 87.77M
- Employees
- 700
- Next earnings
- —
About Rafarma Pharmaceuticals, Inc.
Rafarma Pharmaceuticals, Inc. is a diversified pharmaceutical enterprise that manufactures and distributes a range of medicinal products, including generic antibiotics and specialized drugs, within the Russian market. Its product portfolio encompasses anti-cancer medications, cephalosporin-derived compounds, and non-beta-lactam antibiotics. These are available in various formats such as injectable solutions, ampoules, pediatric suspensions, oral tablets, and capsules. Additionally, Rafarma develops and supplies treatments for injuries, ocular inflammatory conditions, and immunological ailments. In a collaborative effort with PlantEXT Ltd., the company is involved in the research and production of pioneering medical cannabis suppositories, specifically designed for individuals afflicted with inflammatory bowel disease. Originally incorporated as Johnston Acquisition Corp., the firm adopted its current name, Rafarma Pharmaceuticals, Inc., in October 2012. While headquartered in Sandy, Utah, its primary manufacturing and distribution operations are situated in Russia. Since October 19, 2020, Rafarma Pharmaceuticals, Inc. has functioned as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
- ISIN
- US75062C1009
- Listed since
- Dec 11, 2012
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.